start-ver=1.4 cd-journal=joma no-vol=75 cd-vols= no-issue=4 article-no= start-page=431 end-page=437 dt-received= dt-revised= dt-accepted= dt-pub-year=2021 dt-pub=202108 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians en-subtitle= kn-subtitle= en-abstract= kn-abstract=This study aimed to evaluate whether there are differences in the attitudes and practices of cancer pain manage-ment between medical oncologists and palliative care physicians. An online nationwide survey was used to collect responses from board-certified medical oncologists and palliative care physicians in Japan. The survey questionnaire comprised 30 questions. The differences in responses between medical oncologists and palliative care physicians were examined. Out of the 1,227 questionnaires sent, 522 (42.5%) were returned. After apply-ing the exclusion criteria, 445 questionnaires (medical oncologists: n = 283; palliative care physicians: n = 162) were retained for analysis. Among the questions about potential barriers to optimal cancer pain man-agement, both medical oncologists and palliative care physicians considered the reluctance of patients to take opioids due to fear of adverse effects as the greatest barrier. Significantly different ratings between medical oncologists and palliative care physicians were observed on 5 of the 8 questions in this area. Significantly differ-ent ratings were observed for all questions concerning pain specialists and their knowledge. For effective cancer pain management, it is important to account for differences in attitudes and practice between medical oncolo-gists and palliative care physicians. en-copyright= kn-copyright= en-aut-name=KunitomiToshiki en-aut-sei=Kunitomi en-aut-mei=Toshiki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=NasuJunichirou en-aut-sei=Nasu en-aut-mei=Junichirou kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=MinamiDaisuke en-aut-sei=Minami en-aut-mei=Daisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=IwamotoTakayuki en-aut-sei=Iwamoto en-aut-mei=Takayuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=NishieHiroyuki en-aut-sei=Nishie en-aut-mei=Hiroyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SaitoShinya en-aut-sei=Saito en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=FujiwaraToshiyoshi en-aut-sei=Fujiwara en-aut-mei=Toshiyoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=MatsuokaJunji en-aut-sei=Matsuoka en-aut-mei=Junji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= affil-num=1 en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital kn-affil= affil-num=3 en-affil=Palliative Care Team, Okayama University Hospital kn-affil= affil-num=4 en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Palliative Care Team, Okayama University Hospital kn-affil= affil-num=6 en-affil=Palliative Care Team, Okayama University Hospital kn-affil= affil-num=7 en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=8 en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= en-keyword=cancer pain management kn-keyword=cancer pain management en-keyword=opioid kn-keyword=opioid en-keyword=medical oncologist kn-keyword=medical oncologist en-keyword=palliative care physician kn-keyword=palliative care physician en-keyword=barriers kn-keyword=barriers END start-ver=1.4 cd-journal=joma no-vol=126 cd-vols= no-issue=2 article-no= start-page=133 end-page=135 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=20140801 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Treatment for a non-compliant patient with cancer and epilepsy kn-title=癌告知後の精神症状の治療に難渋したてんかん既往のある癌患者の１例 en-subtitle= kn-subtitle= en-abstract= kn-abstract=　A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy. en-copyright= kn-copyright= en-aut-name=MinamiDaisuke en-aut-sei=Minami en-aut-mei=Daisuke kn-aut-name=南大輔 kn-aut-sei=南 kn-aut-mei=大輔 aut-affil-num=1 ORCID= en-aut-name=IchiharaEiki en-aut-sei=Ichihara en-aut-mei=Eiki kn-aut-name=市原英基 kn-aut-sei=市原 kn-aut-mei=英基 aut-affil-num=2 ORCID= en-aut-name=OkabeNobuyuki en-aut-sei=Okabe en-aut-mei=Nobuyuki kn-aut-name=岡部伸幸 kn-aut-sei=岡部 kn-aut-mei=伸幸 aut-affil-num=3 ORCID= en-aut-name=YokomichiNaosuke en-aut-sei=Yokomichi en-aut-mei=Naosuke kn-aut-name=横道直佑 kn-aut-sei=横道 kn-aut-mei=直佑 aut-affil-num=4 ORCID= en-aut-name=KougeNoriko en-aut-sei=Kouge en-aut-mei=Noriko kn-aut-name=高下典子 kn-aut-sei=高下 kn-aut-mei=典子 aut-affil-num=5 ORCID= en-aut-name=KajizonoMakoto en-aut-sei=Kajizono en-aut-mei=Makoto kn-aut-name=鍛治園誠 kn-aut-sei=鍛治園 kn-aut-mei=誠 aut-affil-num=6 ORCID= en-aut-name=AkimotoYutaka en-aut-sei=Akimoto en-aut-mei=Yutaka kn-aut-name=秋元悠 kn-aut-sei=秋元 kn-aut-mei=悠 aut-affil-num=7 ORCID= en-aut-name=HoriKeisuke en-aut-sei=Hori en-aut-mei=Keisuke kn-aut-name=堀圭介 kn-aut-sei=堀 kn-aut-mei=圭介 aut-affil-num=8 ORCID= en-aut-name=MatsubaraMinoru en-aut-sei=Matsubara en-aut-mei=Minoru kn-aut-name=松原稔 kn-aut-sei=松原 kn-aut-mei=稔 aut-affil-num=9 ORCID= en-aut-name=NasuJunichiro en-aut-sei=Nasu en-aut-mei=Junichiro kn-aut-name=那須淳一郎 kn-aut-sei=那須 kn-aut-mei=淳一郎 aut-affil-num=10 ORCID= en-aut-name=TanimotoMitsune en-aut-sei=Tanimoto en-aut-mei=Mitsune kn-aut-name=谷本光音 kn-aut-sei=谷本 kn-aut-mei=光音 aut-affil-num=11 ORCID= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name=木浦勝行 kn-aut-sei=木浦 kn-aut-mei=勝行 aut-affil-num=12 ORCID= en-aut-name=MatsuokaJunzi en-aut-sei=Matsuoka en-aut-mei=Junzi kn-aut-name=松岡順治 kn-aut-sei=松岡 kn-aut-mei=順治 aut-affil-num=13 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　緩和支持医療科 affil-num=2 en-affil= kn-affil=岡山大学病院　血液・腫瘍・呼吸器内科 affil-num=3 en-affil= kn-affil=岡山大学病院　精神科神経科 affil-num=4 en-affil= kn-affil=岡山大学病院　緩和支持医療科 affil-num=5 en-affil= kn-affil=岡山大学病院　看護部 affil-num=6 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=7 en-affil= kn-affil=岡山大学病院　消化器内科 affil-num=8 en-affil= kn-affil=岡山大学病院　消化器内科 affil-num=9 en-affil= kn-affil=岡山大学病院　消化器内科 affil-num=10 en-affil= kn-affil=岡山大学病院　消化器内科 affil-num=11 en-affil= kn-affil=岡山大学病院　血液・腫瘍・呼吸器内科 affil-num=12 en-affil= kn-affil=岡山大学病院　血液・腫瘍・呼吸器内科 affil-num=13 en-affil= kn-affil=岡山大学病院　緩和支持医療科 en-keyword=てんかん（epilepsy） kn-keyword=てんかん（epilepsy） en-keyword=易怒性（irritability） kn-keyword=易怒性（irritability） en-keyword=適応障害（maladjustment） kn-keyword=適応障害（maladjustment） END start-ver=1.4 cd-journal=joma no-vol=127 cd-vols= no-issue=2 article-no= start-page=127 end-page=132 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=20150803 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy kn-title=HER2異常等の低頻度の分子異常を有する非小細胞肺癌の臨床病理学的特徴を明らかにするための前向き観察研究（HER2-CS Study）と標準化学療法後再発・増悪または標準化学療法不応性のHER2陽性非小細胞肺癌患者を対象としたトラスツズマブエムタンシン（遺伝子組換え）の第2相試験 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name=木浦勝行 kn-aut-sei=木浦 kn-aut-mei=勝行 aut-affil-num=1 ORCID= en-aut-name=HottaKatsuyuki en-aut-sei=Hotta en-aut-mei=Katsuyuki kn-aut-name=堀田勝幸 kn-aut-sei=堀田 kn-aut-mei=勝幸 aut-affil-num=2 ORCID= en-aut-name=SatoAkiko en-aut-sei=Sato en-aut-mei=Akiko kn-aut-name=佐藤晃子 kn-aut-sei=佐藤 kn-aut-mei=晃子 aut-affil-num=3 ORCID= en-aut-name=OhashiKadoaki en-aut-sei=Ohashi en-aut-mei=Kadoaki kn-aut-name=大橋圭明 kn-aut-sei=大橋 kn-aut-mei=圭明 aut-affil-num=4 ORCID= en-aut-name=NinomiyaTakashi en-aut-sei=Ninomiya en-aut-mei=Takashi kn-aut-name=二宮崇 kn-aut-sei=二宮 kn-aut-mei=崇 aut-affil-num=5 ORCID= en-aut-name=MinnamiDaisuke en-aut-sei=Minnami en-aut-mei=Daisuke kn-aut-name=南大輔 kn-aut-sei=南 kn-aut-mei=大輔 aut-affil-num=6 ORCID= en-aut-name=TabataMasahiro en-aut-sei=Tabata en-aut-mei=Masahiro kn-aut-name=田端雅弘 kn-aut-sei=田端 kn-aut-mei=雅弘 aut-affil-num=7 ORCID= en-aut-name=KuboToshio en-aut-sei=Kubo en-aut-mei=Toshio kn-aut-name=久保寿夫 kn-aut-sei=久保 kn-aut-mei=寿夫 aut-affil-num=8 ORCID= en-aut-name=KatoYuka en-aut-sei=Kato en-aut-mei=Yuka kn-aut-name=加藤有加 kn-aut-sei=加藤 kn-aut-mei=有加 aut-affil-num=9 ORCID= en-aut-name=HirataTaizo en-aut-sei=Hirata en-aut-mei=Taizo kn-aut-name=平田泰三 kn-aut-sei=平田 kn-aut-mei=泰三 aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院 affil-num=2 en-affil= kn-affil=岡山大学病院 affil-num=3 en-affil= kn-affil=岡山大学病院 affil-num=4 en-affil= kn-affil=岡山大学病院 affil-num=5 en-affil= kn-affil=岡山大学病院 affil-num=6 en-affil= kn-affil=岡山大学病院 affil-num=7 en-affil= kn-affil=岡山大学病院 affil-num=8 en-affil= kn-affil=岡山大学病院 affil-num=9 en-affil= kn-affil=岡山大学病院 affil-num=10 en-affil= kn-affil=岡山大学病院 en-keyword=臨床研究中核病院 kn-keyword=臨床研究中核病院 en-keyword=国立研究開発法人日本医療研究開発機構 kn-keyword=国立研究開発法人日本医療研究開発機構 en-keyword=文部科学省橋渡し研究加速ネットワークプログラム kn-keyword=文部科学省橋渡し研究加速ネットワークプログラム en-keyword=HER2-CS study kn-keyword=HER2-CS study en-keyword=trastuzumab emtansine kn-keyword=trastuzumab emtansine END